Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral Anticoagulant

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 660 participants.

Also called NCT07621796

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 660 participants (planned count) (from the registry)
Sponsor
Hackensack Meridian Health (from the registry)
Registry
  • NCT NCT07621796
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07621796. Randomized; triple masking; primary purpose treatment. Start 2027-01-01 (anticipated); primary completion 2032-01-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral Anticoagulant
Acronym
ESTER-DOAC
Condition
Acute Ischemic Stroke
Intervention (Drug)
Intravenous tenecteplase (TNK)
Intervention (Drug)
Placebo
Lead sponsor
Hackensack Meridian Health (class: other)

Record details

Record id
cardio:ct-nct07621796
Content hash
84ab538dc1a6df32ff0b3511137e11a1700298cf0f3d493fc44a2e0875a12f4c